Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers develop oral gel form of dexmedetomidine
Dogs given the dexmedetomidine gel displayed fewer signs of fear and anxiety than dogs in the placebo group.

Treatment reduces signs of fear and anxiety in dogs

Researchers have developed an oral gel form of dexmedetomidine that may be given by dog owners at home.

A study published in Veterinary Record concludes that the gel “significantly reduced behaviours related to fear and anxiety over time, and the overall effect and success of treatment were found superior to placebo.”

It adds that the dose used was “safe and devoid of any significant clinical sedative effect”. Furthermore, the new form of administration was found by owners to be easy to use across the range of dogs tested.

The innovation, developed by Orion Parma, is now available as a treatment on prescription.

In the study, researchers administered the gel or an identical placebo to 182 dogs with a history of acute anxiety and fear associated with fireworks noise. The experiment took place on New Years’ Eve 2012 and assessed the overall treatment effect in addition to signs and extent of anxiety and fear.

The study reports a higher proportion of dogs had a good or excellent treatment effect in the dexmedetomidine group (72 per cent) than in the placebo group (37 per cent). This means that the dogs did not show any signs of fear and anxiety, or the signs were mild and temporary.

It also reports that dogs given the dexmedetomidine gel displayed fewer signs of fear and anxiety than dogs in the placebo group, including panting, trembling and growling.

While the gel was found by owners to be easy to apply, the authors are reminding vets of the importance of instructing clients carefully on the correct use of new medications. They emphasise that a personalised treatment plan should be set up for every patient covering all appropriate treatment options.

The study has won this year’s Veterinary Record Impact Award for research that is considered likely to have the most significant practical impact by the journal’s research team. It was selected from some 150 papers published by Veterinary Record last year ‘due to its highly practical outcome for an issue often seen by vets in small animal practice’.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.